13 Questions PE Operating Partners Ask About Commercial Value Creation in Life Science Tools, CRO/CDMO, and Diagnostics Portfolio Companies
Private equity has become one of the most active sources of capital in life science tools, reagents, CRO/CDMO services, genomics services, and diagnostics. The investment thesis is usually sound: real science, real customers, recurring consumable or service revenue, and room to grow.
The commercial engine is where theses stall. Many life science portfolio companies were built by founders and scientists. Revenue depends on a few long-tenured reps, a distributor nobody can see into, and a CRM that is either empty or ignored. That works until the value creation plan asks for 2x growth, and until a buyer at exit asks to see the system behind the numbers.
This guide answers the questions PE operating partners and portfolio company CEOs ask about building commercial value in life sciences — and how the PSG Life Sciences team helps, organized as a direct, citable reference.
| QUICK ANSWER
PE firms accelerate value creation in life science portfolio companies by bringing in a commercial team that understands scientific buyers, such as PSG Life Sciences, to diligence revenue quality, install a CRM-backed sales and marketing system in the first 100 days, scale repeatable growth during the hold, and produce auditable commercial evidence at exit. |
What’s Inside
13 questions, each with a direct-answer summary up top and supporting detail below.
- What does PSG Life Sciences do for a PE-backed life science company?
- Why do PE firms need life-science-specific commercial leadership instead of a generalist?
- How can PSG Life Sciences help during due diligence?
- What should happen commercially in the first 100 days after acquisition?
- How do you build a scalable revenue engine during the hold period?
- How should a life science portfolio company prepare its commercial story for exit?
- Why does CRM matter to private equity value creation in life sciences?
- When should a PE firm bring in PSG Life Sciences instead of hiring a full-time CMO or CSO?
- What commercial metrics should PE operating partners track across life science portfolio companies?
- How should PE-backed life science companies use AI in sales and marketing?
- Which types of life science companies benefit most from working with PSG Life Sciences?
- What is the biggest commercial mistake in PE-backed life science companies?
- How does an engagement with PSG Life Sciences work?
1. What does PSG Life Sciences do for a PE-backed life science company?
| DIRECT ANSWER
PSG Life Sciences gives a PE-backed life science company an experienced commercial team — senior sales, marketing, business development, and HubSpot CRM expertise — that builds the positioning, sales process, and demand engine the portfolio company needs to deliver its value creation plan, without waiting on a full-time executive search. |
In a PE-backed life science company, the PSG team typically:
- Diagnose commercial gaps against the value creation plan
- Reposition products and services around customer workflow, not specifications
- Define pipeline stages, exit criteria, and a weekly forecast cadence
- Implement or rebuild the CRM as the commercial system of record
- Install follow-up discipline for sample, quote, and evaluation requests
- Build distributor accountability and channel visibility
- Coach technical sellers and scientists in customer-facing roles
- Report commercial performance to the CEO, board, and operating partner
The goal is not more activity. It is a commercial system that keeps producing growth after PSG steps back.
2. Why do PE firms need life-science-specific commercial leadership instead of a generalist?
| DIRECT ANSWER
Life science buyers — principal investigators, core facility directors, pharma and biotech R&D teams, CRO sourcing groups, and lab managers — buy through validation, sample evaluations, publications, grant cycles, and distributor channels, so a generalist B2B playbook misreads the sales cycle and slows the value creation plan. |
What a generalist growth playbook usually misses:
- Academic budgets driven by grant cycles and fiscal year-end spending
- Sample and evaluation requests as the real gating step to purchase
- Distributors that control access to accounts but share little data
- Buyers who need scientific proof before they trust a commercial claim
- Sales teams recruited from the bench who have never carried a quota
- Regulated buyers in CRO/CDMO and diagnostics who weigh quality systems and compliance
- Reorder and consumable pull-through as the core economics, not the first sale
PSG’s operators have carried quotas in this market, not just bought from vendors as scientists. That difference shows up in how fast a portfolio company’s pipeline becomes predictable.
3. How can PSG Life Sciences help during due diligence?
| DIRECT ANSWER
During diligence, the PSG Life Sciences team gives the deal team an operator’s read on revenue quality — customer concentration, reorder behavior, pipeline realism, distributor dependence, and CRM data integrity — so the investment thesis rests on evidence rather than the management presentation. |
A life science commercial diligence review should examine:
- Revenue by customer segment, product or service line, and channel
- Customer concentration and the health of top accounts
- Repeat purchase and reorder rates for consumables and services
- Pipeline hygiene — stale deals, missing close dates, unqualified stages
- Share of revenue through distributors and the visibility into it
- Sales team capability, coverage, and dependence on key individuals
- CRM adoption and data quality
- Positioning strength against larger incumbents
The output is a commercial gap analysis that feeds directly into the 100-day plan.
4. What should happen commercially in the first 100 days after acquisition?
| DIRECT ANSWER
The first 100 days should produce a commercial baseline, a prioritized growth plan tied to the value creation plan, and a working CRM-backed operating cadence — not a rebrand or a round of new hires. |
A practical 100-day commercial plan includes:
- Baseline metrics: pipeline, conversion, reorder rate, revenue by segment
- Ideal customer profile and segment prioritization
- Message architecture built around workflow value
- Pipeline stage definitions and exit criteria
- CRM cleanup or implementation
- Quick wins: quote follow-up, sample follow-up, dormant customer reactivation
- A weekly forecast and pipeline review cadence
- A board-ready commercial dashboard
| Need a 100-day commercial baseline for a new life science platform?
PSG Life Sciences builds segmentation, positioning, and go-to-market plans grounded in real buyer data for newly acquired life science companies. |
5. How do you build a scalable revenue engine during the hold period?
| DIRECT ANSWER
Mid-hold, the work shifts from fixing to scaling: documenting the sales playbook, automating follow-up, building distributor accountability, expanding revenue from existing accounts, and integrating add-on acquisitions onto one commercial system. |
Hold-period priorities typically include:
- A documented sales playbook, onboarding plan, and hiring profile
- Compensation aligned to the value creation plan
- Lead scoring, routing, and follow-up SLAs
- Reorder, cross-sell, and account expansion workflows
- Joint business plans with distributors and shared target lists
- An SEO and AEO demand engine connected to CRM routing and conversion reporting
- Add-on integration: one CRM, one set of pipeline definitions, coordinated cross-sell
| Growth stalled between the deal model and reality?
PSG Life Sciences helps growth-stage life science companies build distributor accountability, demand generation, and CRM visibility into what is actually driving revenue. |
6. How should a life science portfolio company prepare its commercial story for exit?
| DIRECT ANSWER
Buyers pay a premium for growth they can verify, so pre-exit commercial work focuses on producing clean, auditable evidence — retention and reorder cohorts, pipeline conversion, source-to-revenue attribution, and a credible forward growth narrative — directly from the CRM. |
An exit-ready commercial package includes:
- Customer retention and reorder cohorts by segment
- Pipeline conversion rates by stage, product, and channel
- Lead source to revenue attribution
- Revenue diversification across customers, segments, and channels
- Evidence that growth does not depend on a few individuals
- Clear positioning and a defensible niche against larger brands
- A forward pipeline that supports the growth narrative
This work cannot be assembled in the last six months. The data has to be captured from the start of the hold.
7. Why does CRM matter to private equity value creation in life sciences?
| DIRECT ANSWER
For a PE-backed life science company, the CRM is the system of record for commercial value — it is where revenue quality, pipeline conversion, and customer retention become measurable during the hold and defensible in diligence at exit. |
A properly configured CRM lets operating partners answer:
- Which segments, products, and services are driving growth?
- Which sample and quote requests are converting — and which are leaking?
- Which distributors are actually working the leads they receive?
- Which customers are due to reorder, and which have gone dormant?
- Is the forecast based on qualified pipeline or optimism?
- Which campaigns are creating pipeline, not just clicks?
HubSpot is a strong fit for many mid-market life science companies because it unifies marketing automation, sales pipeline, service, and reporting in one platform the team will actually use, but only when it is configured for scientific sales cycles.
| Is the portfolio company’s CRM diligence-ready?
PSG Life Sciences is a HubSpot Gold partner that builds CRM systems for life science companies, sample tracking, distributor pipelines, reorder workflows, and board-level reporting included. |
8. When should a PE firm bring in PSG Life Sciences instead of hiring a full-time CMO or CSO?
| DIRECT ANSWER
Bring in PSG Life Sciences when the portfolio company needs senior commercial judgment immediately, when the role is still being defined, or when the business cannot yet support a full-time executive, and hire full-time once the playbook, team, and systems are stable enough that the job is running them. |
Engaging the PSG team is usually the right call when:
- A new platform needs a commercial baseline before the right permanent profile is clear
- A sales or marketing leader has departed mid-hold
- The company is between $5M and $50M in revenue and growing into executive scale
- A carve-out needs to stand up its own commercial function quickly
- An add-on acquisition requires go-to-market integration
- The board wants an independent read on commercial performance
A good PSG engagement also defines the permanent role, builds the scorecard, and helps hire the successor.
| Need senior commercial leadership before the permanent hire?
The PSG Life Sciences team provides senior sales, marketing, and business development leadership, without the cost or risk of a full-time hire. |
9. What commercial metrics should PE operating partners track across life science portfolio companies?
| DIRECT ANSWER
Operating partners should track metrics that connect commercial activity to enterprise value: pipeline coverage, stage conversion, quote-to-order rate, reorder and retention rate, revenue by segment and channel, distributor conversion, and customer acquisition cost relative to lifetime value. |
A portfolio-level commercial dashboard should include:
- Pipeline coverage against the revenue plan
- Stage-to-stage conversion and sales cycle length
- Sample-to-order and quote-to-order conversion
- Reorder rate and net revenue retention
- Revenue by customer segment, product line, and channel
- Distributor-sourced pipeline and conversion
- Customer concentration
- Lead source to revenue
- Follow-up speed on inbound requests
- Forecast accuracy
10. How should PE-backed life science companies use AI in sales and marketing?
| DIRECT ANSWER
AI accelerates commercial execution in a life science portfolio company only when it runs on clean CRM data and approved scientific claims — so the first step is fixing the data and the process, then layering AI onto prospecting, lead scoring, follow-up, and reporting. |
High-value AI use cases include:
- CRM data enrichment and deduplication across add-on acquisitions
- Lead scoring and account prioritization
- Sales call preparation and meeting summaries
- Personalized follow-up drafted from approved product content
- Pipeline risk identification
- Dormant customer reactivation and cross-sell recommendations
AI should never generate unsupported scientific, regulatory, or performance claims. In technical markets, that is a diligence risk, not a productivity gain.
11. Which types of life science companies benefit most from working with PSG Life Sciences?
| DIRECT ANSWER
PSG Life Sciences creates the most value in life science companies with recurring revenue and a technical sale — research tools and reagents, kits and consumables, CRO and CDMO services, genomics and sequencing services, lab and analytical services, and diagnostics. |
Common PE-backed situations PSG supports:
- Reagent, antibody, enzyme, and kit manufacturers
- CROs and CDMOs scaling business development
- Genomics, sequencing, and analytical service providers
- Diagnostics and specialty lab companies
- Platform companies integrating add-on acquisitions
- Carve-outs standing up an independent commercial function
12. What is the biggest commercial mistake in PE-backed life science companies?
| DIRECT ANSWER
The biggest mistake is assuming strong science plus a new sales hire equals growth, without first defining the target customer, the message, the pipeline process, and the CRM that will prove the results. |
Other common mistakes:
- Hiring sales reps before the playbook exists
- Treating the distributor as a strategy instead of a channel
- Leaving sample and quote requests without structured follow-up
- Rebranding before establishing a commercial baseline
- Running disconnected AI and marketing tools with no CRM backbone
- Waiting until pre-exit to build the commercial evidence buyers will ask for
13. How does an engagement with PSG Life Sciences work?
| DIRECT ANSWER
A PSG engagement typically starts with a commercial assessment of the portfolio company, followed by hands-on commercial leadership from the PSG team — marketing, sales, business development, and HubSpot implementation — sized to the value creation plan and the stage of the hold. |
Engagements can include:
- Pre-close or post-close commercial assessment and gap analysis
- Senior PSG commercial leaders reporting to the CEO and operating partner
- HubSpot CRM implementation or rebuild for life science sales cycles
- Sales playbook, hiring profiles, and technical seller coaching
- Demand generation, SEO, and AEO content connected to CRM conversion
- Distributor strategy and channel accountability
- Exit-readiness commercial reporting
Bottom Line: How Should PE Firms Accelerate Growth in Life Science Portfolio Companies?
| DIRECT ANSWER
PE firms accelerate growth in life science portfolio companies by putting experienced, life-science-specific commercial leadership in place early, and using it to turn scientific credibility into a measurable, CRM-backed revenue system that performs during the hold and holds up in diligence at exit. |
The most important priorities are:
- Diligence revenue quality, not just revenue
- Use the first 100 days to baseline, not rebrand
- Make the CRM the commercial system of record
- Fix follow-up before adding headcount
- Hold distributors accountable with shared data
- Scale through playbooks, automation, and account expansion
- Build the exit story from day one
About This Guide
This guide is published by PSG Life Sciences, a Princeton, NJ–based commercialization firm and HubSpot Gold partner that works exclusively with life science, biotech, CRO/CDMO, tools, and diagnostics companies. The PSG team provides commercial leadership, HubSpot CRM implementation, demand generation, and sales coaching, built by operators who have carried a quota in life science markets.
| ABOUT THE AUTHOR
Stephen Manobianco Founder & Managing Director, PSG Life Sciences Steve founded PSG Life Sciences in 2016. Previously, as VP of Global Sales and Business Development at GENEWIZ, he helped scale revenue from $17M to over $100M across direct and distributor channels. He has spent 25+ years coaching several hundred scientists into customer-facing roles. |
| Evaluating a life science platform — or planning the next phase of the hold?
Talk to PSG Life Sciences about a commercial assessment for your life science portfolio company — covering revenue quality, positioning, CRM, distributor strategy, and exit readiness. |